{"blog": [], "keywords": [{"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "1", "is_major": "N"}, {"value": "Endo International PLC", "name": "organizations", "rank": "2", "is_major": "N"}, {"value": "Par Pharmaceutical Cos Inc", "name": "organizations", "rank": "3", "is_major": "N"}, {"value": "TPG Capital", "name": "organizations", "rank": "4", "is_major": "N"}, {"value": "Bonderman, David", "name": "persons", "rank": "5", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "6", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/05/19/business/dealbook/tpgs-8-billion-drug-sale-a-rare-development.html", "document_type": "article", "byline": {"person": [{"lastname": "CYRAN", "firstname": "Robert", "role": "reported", "organization": "", "rank": 1}], "original": "By ROBERT CYRAN"}, "type_of_material": "News", "multimedia": [], "section_name": "Business Day", "word_count": "378", "source": "The New York Times", "subsection_name": "DealBook", "lead_paragraph": "With the sale of Par Pharmaceutical, the buyout firm will generate an eightfold return on its investment in three years.", "pub_date": "2015-05-19T00:00:00Z", "news_desk": "Business", "headline": {"kicker": "Breakingviews", "main": "TPG\u2019s $8 Billion Drug Sale a Rare Development", "content_kicker": "Breakingviews"}, "print_page": null, "snippet": "With the sale of Par Pharmaceutical, the buyout firm will generate an eightfold return on its investment in three years.", "_id": "555a34b038f0d803a0965b90", "slideshow_credits": null, "abstract": null}